The wait is almost over. The highest-rated, most-anticipated abstracts submitted for WCLC 2022 will be presented tomorrow, Monday, August 8, during the Presidential Symposium moderated by IASLC President Heather Wakelee, MD, FASCO, and Conference Co-Chair Eric Lim, MD. The plenary session will begin 08:30-10:20 in Hall C1. The session will also be live streamed and available on-demand via the WCLC virtual platform or mobile app.
During the symposium, data from four abstracts will be presented:
- Personalised Smoking Cessation Support in a Lung Cancer Screening Programme: The Yorkshire Enhanced Stop Smoking Study (YESS)
- Lobar or Sub-lobar Resection for Peripheral Clinical Stage IA = 2 cm Non-small Cell Lung Cancer (NSCLC): Results From an International Randomized Phase III Trial (CALGB 140503 [Alliance])
- IMpower010: Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC
- Progression Free Survival and Overall Survival in NADIM II Study
“The Presidential Symposium is top on my list of must-see sessions,” IASLC CEO Karen Kelly said. “The past year-and-a-half has really been about early-stage disease. It’s been great to see the therapeutic advances in advanced disease move to the early-stage setting. Now, we have two immune checkpoint inhibitors approved in early-stage disease, but they were approved based on the disease-free survival endpoint, so we are anxious to hear the data on overall survival (OS) from the IMpower010 trial.”
Plenary 3: Presidential Symposium—Top Rated Abstracts
- Time: 08:30-10:20 CEST
- Date: Monday, August 8
- Location: Hall C1, Live & On-Demand
- Moderators: Heather Wakelee, MD, FASCO; Eric Lim, MD
Dr. Kelly said the progression-free survival (PFS) and OS from the NADIM II is also highly anticipated in the lung cancer community.
“In June, we saw the impressive major pathological response rate with the combination of chemotherapy and an immune checkpoint inhibitor, but we need to translate that into PFS and OS, so it will be interesting to hear the PFS data during the Presidential Symposium,” she said. “And we’re still trying to understand the best resection approach for patients with small tumors. We learned many years ago—before CT screening was available—that a limited resection was not as good because the local recurrence rate was high. Now we’ll see data from the Alliance trial comparing lobar and sub-lobar resection in smaller tumors of 2 centimeters or less. These are important results because now we have CT screening, and we may find more than one nodule. Having data on the best approach to these small tumors will be very valuable to our patient population.”
However, she said, smoking cessation is key to decreasing the mortality of lung cancer, so the data from YESS, which examined personalized smoking cessation support as part of a lung cancer screening program, will also be very valuable.
Monday’s program will also include many interactive breakfast sessions, education sessions, and abstract sessions. The Exhibit Hall will be open from 09:45-19:00 in Hall B. Be sure to stop by the Exhibit Hall from 17:00-19:00, when Poster Presenters will be available to discuss their research.